Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Diffuse Intrinsic Pontine Glioma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Obesity 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Glioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease 1Carcinosarcoma 1

Interventions

Carboplatin 18Paclitaxel 17Bevacizumab 17olaparib 8Specimen Handling 7liposomal doxorubicin 6pembrolizumab 5Taxes 5Biopsy 5cemiplimab 4Magnetic Resonance Spectroscopy 4sarilumab 3niraparib 3mirvetuximab soravtansine 3Topotecan 3Standard of Care 3Letrozole 3Gemcitabine 3Cisplatin 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2palbociclib 2abemaciclib 2Temozolomide 2Surgical Procedures, Operative 2Practice Guidelines as Topic 2Poly(ADP-ribose) Polymerase Inhibitors 2Immunoglobulin G 2Fulvestrant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Fallopian Tube Neoplasms × TIC10 compound × Clear all
NCT04055649 2025-06-18

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
62 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡